An FDA advisory panel recommended loosening restrictions on two [1] unapproved peptide drugs to allow compounding pharmacies to produce them.

This move signals a potential shift in how the agency manages substances popular in the wellness community, despite warnings from career scientists about safety and efficacy.

The federal health advisory committee met in Washington, D.C., to determine if these substances should be added to the list of materials that compounding pharmacies may safely produce. The panel narrowly backed the move to ease restrictions on the two [1] peptides.

Some reports indicate that the recommendation covers several peptides, including BPC-157, though other sources specify only two [1]. These substances have gained traction among wellness influencers and have been advocated for by Robert F. Kennedy Jr.

Career scientists within the FDA expressed strong objections to the recommendation. These experts said the unproven chemicals should not be used, citing a lack of rigorous clinical data to support their safety for general patient use.

The decision follows a period of increased demand for these peptides. The panel included experts who have promoted the chemicals favored by Robert F. Kennedy Jr., contributing to the narrow vote in favor of the restriction lift.

Compounding pharmacies create customized medications for patients. If the FDA follows the panel's recommendation, these pharmacies would have a clearer legal path to produce these specific peptides without facing the same restrictions currently applied to unapproved substances.

“An FDA advisory panel recommended loosening restrictions on two unapproved peptide drugs.”

The panel's recommendation highlights a growing tension between traditional regulatory science and the influence of the wellness-advocacy movement. By potentially allowing compounding pharmacies to produce unapproved peptides, the FDA may be acknowledging consumer demand over the absence of formal clinical trials, which could lower the barrier for unproven treatments to enter the mainstream medical market.